Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:01 31/05/2024 BST			5-day change	1st Jan Change
142.6 ^USD	-5.89%		-14.43%	+43.36%

05-31	Health Care Stocks Climb On Drug News -- Health Care Roundup	DJ
05-31	Equities Mostly Rise as Fed's Preferred Inflation Measure Meets Street Views	MT

Moderna : 2023 Shareholder Letter

January 02, 2024 at 12:03 pm

View All News

Moderna 2023 Shareholder Letter

January 2, 2024

Moderna has added its 2023 Shareholder Letter from CEO Stéphane Bancel to its website

As we reflect on the past year, our commitment to leveraging mRNA to deliver transformative medicines for patients has never been stronger. We have the platform, technology, resources and the team to establish a new era of medicine. In his annual shareholder letter, Moderna CEO Stéphane Bancel provides updates on our journey to advance our Mission to deliver the greatest possible impact to people through mRNA medicines.

Click here to read the full 2023 Shareholder Letter from Moderna CEO Stéphane Bancel

View All News

Attachments

Original Link
Original Document
Permalink

Disclaimer

Moderna Inc. published this content on 02 January 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 January 2024 12:02:44 UTC.

Latest news about Moderna, Inc.

Health Care Stocks Climb On Drug News -- Health Care Roundup	05-31	DJ
Equities Mostly Rise as Fed's Preferred Inflation Measure Meets Street Views	05-31	MT
Equities Mostly Rise as Fed's Preferred Inflation Measure Meets Expectations	05-31	MT
RBC Raises Moderna's Price Target to $160 From $135	05-31	MT
Moderna Gets FDA Approval For Respiratory Syncytial Virus Vaccine for Seniors	05-31	MT
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars	05-31	MT
Moderna Secures FDA Approval for mRESVIA Vaccine	05-31	MT
Moderna Gets FDA Approval For RSV Vaccine	05-31	MT
Moderna Gets FDA Approval For RSV Vaccine mRESVIA	05-31	MT
US FDA approves Moderna's RSV vaccine, its second marketed product	05-31	RE
Transcript : Moderna, Inc. Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-31-2024 10:00 AM	05-31
Health Care Stocks Steady -- Health Care Roundup	05-30	DJ
News Highlights : Top Company News of the Day - Thursday at 3 PM ET	05-30	DJ
News Highlights : Top Company News of the Day - Thursday at 1 PM ET	05-30	DJ
News Highlights : Top Company News of the Day - Thursday at 11 AM ET	05-30	DJ
A new phase for the market	05-30
Futures slip as rate-cut uncertainty persists; data on tap	05-30	RE
US nears deal to fund Moderna's bird flu vaccine trial, FT reports	05-30	RE
U.S. close to deal to bankroll Moderna's bird flu vaccine trial, FT reports	05-30	RE
US CLOSE TO DEAL TO BANKROLL MODERNA BIRD FLU VACCINE TRIAL - FT…	05-30	RE
BioNTech gets $145 mln funding for African vaccine plants	05-29	RE
News Highlights : Top Company News of the Day - Tuesday at 5 PM ET	05-28	DJ
News Highlights : Top Company News of the Day - Tuesday at 7 PM ET	05-28	DJ
Nasdaq Closes Above 17,000 for First Time Amid Nvidia Rally	05-28	MT
Nasdaq Closes Above 17,000 for First Time on Nvidia Rally	05-28	MT

Chart Moderna, Inc.

Duration

Period

More charts

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

Biotechnology & Medical Research

Calendar

03/06/2024 - American Society of Clinical Oncology Meeting - Abstract: #LBA9512

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 02:24 pm

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 16, 2024 at 08:31 pm

More Strategies

Ratings for Moderna, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

142.6 USD

Average target price

139.9 USD

Spread / Average Target

-1.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research